Arthneeti

Gennex Laboratories Share Price & Earnings Call Analysis

₹8.21+2.37% today
Market cap
₹199 Cr
P/E
10.61
ROE
10.52%
PEG
0.16
Price to sales
1.09
Debt to equity
0.16
52W high / low
₹16.0 / ₹7.13
Sales growth (5Y)
23.70%
EBITDA margin
14.42%
Net profit margin
12.46%
Promoter holding
23.63%
Sales (last year)
₹183 Cr

Incorporated in 1995, Gennex Laboratories Ltd manufactures Bulk Drugs and Intermediaries[1]

Potential multibaggers · Q2 FY27

Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance

  1. Strong growth
    2
  2. Strong growth
    1
  3. Strong growth
    3
See all potential multibaggersWhere does Gennex Laboratories rank?

Portfolio builder

Build your portfolio
from the top-ranked stocks

  1. 1. Pick 3–15 stocks
  2. 2. Choose large, mid or small cap and your sectors
  3. 3. Get a portfolio built from the rankings
Build my portfolio

Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.

Peers

Pharmaceuticals & Biotechnology companies ranked on guidance

#CompanyRevenue guidedMargin guidedMarket capP/E
140%+Up 2%+₹480 Cr19.1
240%+Up 0–2%₹212 Cr16.1
340%+Flat₹17,925 Cr—
440%+Flat₹5,223 Cr39.1
540%+Flat₹40 Cr—
620–40%Up 2%+₹51,093 Cr44.6

Sign up free to see every company in the sector ranking and track Gennex Laboratories.

Pro shows every company guiding 40%+ revenue growth →Full Pharmaceuticals & Biotechnology ranking

Financials of Gennex Laboratories

Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.

Financials of Gennex Laboratories

Quarterly Results

Quarter-by-quarter operating performance

Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Sales +14.6320.8016.5218.1821.3935.5228.3233.3840.0140.3334.1839.3042.96
Expenses +12.8117.2811.4212.4116.5929.2624.1025.9232.8638.3129.1131.7434.39
Operating Profit1.823.525.105.774.806.264.227.467.152.025.077.568.57
OPM %12.44%16.92%30.87%31.74%22.44%17.62%14.90%22.35%17.87%5.01%14.83%19.24%19.95%
Other Income +0.000.000.000.000.000.002.470.000.003.682.280.00-0.30
Interest0.190.630.730.780.830.730.730.220.841.200.981.031.11
Depreciation0.180.370.651.030.450.230.451.110.500.540.500.470.52
Profit before tax1.452.523.723.963.525.305.516.135.813.965.876.066.64
Tax %24.83%19.05%23.39%22.47%21.31%15.28%15.43%12.23%12.91%22.22%14.48%9.08%9.79%
Net Profit +1.082.042.853.072.764.504.665.385.063.075.015.516.00
EPS in Rs0.070.120.160.170.150.200.190.210.200.100.200.210.22

Financials of Gennex Laboratories

Profit & Loss

Annual income statement trend

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales +4244565660616687138157
Expenses +3742525253566170121134
Operating Profit5243755171723
OPM %11%5%7%6%11%9%7%20%12%15%
Other Income +01110145106
Interest1111111344
Depreciation1111111222
Profit before tax3133556162123
Tax %13%42%26%27%20%23%23%20%15%
Net Profit +3122445131820
EPS in Rs0.140.040.120.100.210.210.280.580.800.73
Dividend Payout %0%0%0%0%0%0%0%0%0%

Financials of Gennex Laboratories

Balance Sheet

Capital structure and asset base

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital13131313131318232324
Reserves18192123273162148164189
Borrowings +4255710161088
Other Liabilities +14161316121451545955
Total Liabilities495052575968132230256357
Fixed Assets +16161615141474566076
CWIP0000000250
Investments7777770000
Other Assets +26282935384859172191281
Total Assets495052575968132230256357

Financials of Gennex Laboratories

Cash Flows

Operating, investing and financing cash movement

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity +-032-2-11224-47-11
Cash from Investing Activity +-1-1-1-0-0-2-38191
Cash from Financing Activity +1-21-02-221745
Net Cash Flow-002-208646-5
Free Cash Flow-121-2-210-16-31-20
CFO/OP13%190%55%-52%1%242%505%-274%-45%

Financials of Gennex Laboratories

Ratios

Working capital efficiency and return ratios

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days908768415567527537
Inventory Days433157785072139184133
Days Payable139161888659726311149
Cash Conversion Cycle-7-4338344667129148122
Working Capital Days747556871088723255214
ROCE %6%11%8%14%12%11%14%13%

Continue your research

Others in Pharmaceuticals & Biotechnology this season

  • Neuland Laboratories (Q2 FY27)

    Q2FY27 Total Income (revenue) was ₹457.2 crore, down 11.4% year-on-year (YoY) from Q2FY26. Key investor presentation takeaways from Neuland Laboratories Ltd's Q

  • Hikal (Q2 FY27)

    Consolidated Revenue Q2FY27:** ₹434 crores, up 36% YoY from ₹319 crores in Q2FY26 (Page 9) . Key investor presentation takeaways from Hikal Ltd's Q2 FY27 invest

  • Kopran (Q2 FY27)

    9,335 lakhs (~79% increase) . Key investor presentation takeaways from Kopran Ltd's Q2 FY27 investor presentation — and how it ranks against sector peers.

  • Emcure Pharma (Q2 FY27)

    Q2FY27 Revenue from Operations: INR 28,205 Mn, up 24.3% YoY (Page 9). Key investor presentation takeaways from Emcure Pharmaceuticals Ltd's Q2 FY27 investor pre

Compare:vs Sun Pharmaceutical Industriesvs Divis Laboratoriesvs Torrent Pharmaceuticals